OBJECTIVE:Intermittent antegrade warm blood cardioplegia (IAWBC) is a simple and cost-effective method of myocardial preservation. However, there are only few prospective trials comparing this type of cardioplegia to established cardioplegic strategies in elective on-pump coronary surgery with respect to myocardial protection and outcome. METHODS: In a prospective, randomized trial IAWBC (33 degrees C) (n=100) was compared to intermittent antegradecold (4 degrees C) blood cardioplegia (n=100), regarding clinical outcome and myocardial protection using cardiac troponin-I (cTNI) and creatine kinase MB isoenzyme (CK-MB) measurements to assess ischemia. RESULTS: Preoperative parameters were comparable in both groups. Results demonstrated no differences in-between the groups regarding mortality (2.0% both), incidence of perioperative myocardial infarction (2 versus 3%), need for intra-aortic balloon pump (3 versus 4%), length of ICU stay (2.0+/-2.5 versus 2.1+/-3.0 days) and incidence of postoperative atrial fibrillation (41 versus 34%). However, the necessity of defibrillation after cardiac arrest (18 versus 43%, P<0.001) was significantly less frequent and of lower intensity (3.4+/-10.8 versus 10.8+/-20.6 J, P<0.001) in the IAWBC-group. Postoperatively the ischemia markers were significantly lower in the IAWBC-group, cTNI within the first 72 h (from P<0.001 to P=0.013) and even CK-MB within the first 24 h (from P=0.004 to P<0.011). CONCLUSION:IAWBC is a safe and simple method in elective on-pump coronary artery bypass surgery. Significantly lower ischemic markers suggest an improved myocardial protection compared to cold blood cardioplegia in these patients.
RCT Entities:
OBJECTIVE: Intermittent antegrade warm blood cardioplegia (IAWBC) is a simple and cost-effective method of myocardial preservation. However, there are only few prospective trials comparing this type of cardioplegia to established cardioplegic strategies in elective on-pump coronary surgery with respect to myocardial protection and outcome. METHODS: In a prospective, randomized trial IAWBC (33 degrees C) (n=100) was compared to intermittent antegrade cold (4 degrees C) blood cardioplegia (n=100), regarding clinical outcome and myocardial protection using cardiac troponin-I (cTNI) and creatine kinase MB isoenzyme (CK-MB) measurements to assess ischemia. RESULTS: Preoperative parameters were comparable in both groups. Results demonstrated no differences in-between the groups regarding mortality (2.0% both), incidence of perioperative myocardial infarction (2 versus 3%), need for intra-aortic balloon pump (3 versus 4%), length of ICU stay (2.0+/-2.5 versus 2.1+/-3.0 days) and incidence of postoperative atrial fibrillation (41 versus 34%). However, the necessity of defibrillation after cardiac arrest (18 versus 43%, P<0.001) was significantly less frequent and of lower intensity (3.4+/-10.8 versus 10.8+/-20.6 J, P<0.001) in the IAWBC-group. Postoperatively the ischemia markers were significantly lower in the IAWBC-group, cTNI within the first 72 h (from P<0.001 to P=0.013) and even CK-MB within the first 24 h (from P=0.004 to P<0.011). CONCLUSION:IAWBC is a safe and simple method in elective on-pump coronary artery bypass surgery. Significantly lower ischemic markers suggest an improved myocardial protection compared to cold blood cardioplegia in these patients.
Authors: Michele Di Mauro; Antonio M Calafiore; Antonino Di Franco; Francesco Nicolini; Francesco Formica; Roberto Scrofani; Carlo Antona; Antonio Messina; Giovanni Troise; Giovanni Mariscalco; Cesare Beghi; Michele De Bonis; Cinzia Trumello; Antonio Miceli; Mattia Glauber; Marco Ranucci; Carlo De Vincentiis; Mario Gaudino; Roberto Lorusso Journal: Int J Cardiol Date: 2020-10-04 Impact factor: 4.164
Authors: Sarkis M Minasian; Michael M Galagudza; Yuri V Dmitriev; Dmitry I Kurapeev; Timur D Vlasov Journal: J Cardiothorac Surg Date: 2013-04-02 Impact factor: 1.637
Authors: Elmar W Kuhn; Yeong-Hoon Choi; Jung-Min Pyun; Klaus Neef; Oliver J Liakopoulos; Christof Stamm; Thorsten Wittwer; Thorsten Wahlers Journal: Biomed Res Int Date: 2015-05-19 Impact factor: 3.411